Focus on anti-atherosclerotic therapy

Area of Science:

• Pharmacology
• Cardiovascular Research
• Biochemistry

Background:

• Calcium antagonists (CA) demonstrate anti-atherosclerotic effects by reducing arterial cholesterol accumulation.
• Previous research indicates varied effects of different CA compounds on low-density lipoprotein (LDL) uptake.

Purpose of the Study:

• To investigate the mechanism by which CA influence LDL metabolism in the arterial wall.
• To determine if specific structural features of CA are responsible for modulating LDL receptor activity.

Main Methods:

• Assessing receptor-mediated LDL uptake in human fibroblasts stimulated by various CA compounds.
• Testing CA activity in cell lines from patients with different forms of familial hypercholesterolemia (FH).
• Evaluating the presence of a basic group on CA molecules and its correlation with LDL receptor modulation.

Main Results:

• Verapamil and diltiazem (verapamil-like) stimulated LDL receptor activity in normal and heterozygous FH fibroblasts, but not in homozygous FH fibroblasts.
• Nifedipine-like compounds and flunarizine showed no effect on LDL receptor activity.
• A basic group on the CA molecule appears necessary for modulating LDL receptor expression.
• Preliminary data suggest CA can reach effective concentrations in the aortic wall.

Conclusions:

• Specific calcium antagonists, like verapamil and diltiazem, can stimulate LDL receptor activity, potentially improving lipid metabolism in the arterial wall.
• The presence of a basic group on the CA molecule is crucial for this LDL receptor modulation.
• These findings highlight a novel mechanism for the anti-atherosclerotic effects of certain calcium antagonists.